Key facts
- Kemai Biotechnology’s last known valuation is $29.5M (Nov 2025).
- Notable investors include Wuxi Capital, Hualan New Pharmaceutical Material, XtalPi Technology.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Kemai Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Kemai Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kemai Biotechnology
Developer of computational biopharmaceutical technologies intended for targeting defined epitopes without animal immunization or library screening. The company offers in silico generation and sequence optimization, enabling biopharma industry users to access a third source for antibody discovery solutions.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Ownership
- Acquired/Merged (Operating Subsidiary)
Kemai Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kemai Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kemai Biotechnology in its N-PORT filings yet. We sweep new filings monthly.